Scholar Rock Holding (SRRK) Research & Development (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Research & Development came in at $51.8 million in Q1 2026, up 6.44% year-on-year from $48.7 million in Q1 2025, and up 10.54% quarter-over-quarter from $46.9 million in Q4 2025.
Scholar Rock Holding (SRRK) Research & Development (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Research & Development history runs 10 years deep, the most recent figure standing at $51.8 million for Q1 2026.
- On a quarterly basis, Research & Development rose 6.44% year-over-year to $51.8 million in Q1 2026; TTM through Mar 2026 was $211.6 million, a 11.28% increase from a year earlier, with the FY2025 full-year figure at $208.4 million, up 12.95% from the prior year.
- Research & Development improved to $51.8 million in Q1 2026 per SRRK's latest filing, from $46.9 million in the prior quarter.
- Across five years, Research & Development topped out at $62.4 million in Q2 2025 and bottomed at $26.9 million in Q2 2023.
- The 5-year median for Research & Development is $42.4 million (2024), against an average of $40.7 million.
- Across the five-year window, Research & Development slipped 16.23% in 2023 and soared 60.59% in 2024, its largest moves.
- Year by year, Research & Development stood at $29.6 million in 2022, then gained by 18.06% to $35.0 million in 2023, then soared by 44.06% to $50.4 million in 2024, then fell by 6.93% to $46.9 million in 2025, then climbed by 10.54% to $51.8 million in 2026.
- Per Business Quant, the three latest SRRK Research & Development figures stand at $51.8 million (Q1 2026), $46.9 million (Q4 2025), and $50.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Scholar Rock Holding | 6.10 Bn | 6.10 Bn | - | 51.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.81 Mn |
| Dec 31, 2025 | 46.88 Mn |
| Sep 30, 2025 | 50.49 Mn |
| Jun 30, 2025 | 62.40 Mn |
| Mar 31, 2025 | 48.68 Mn |
| Dec 31, 2024 | 50.37 Mn |
| Sep 30, 2024 | 48.72 Mn |
| Jun 30, 2024 | 42.37 Mn |
| Mar 31, 2024 | 43.09 Mn |
| Dec 31, 2023 | 34.96 Mn |
| Sep 30, 2023 | 30.34 Mn |
| Jun 30, 2023 | 26.87 Mn |
| Mar 31, 2023 | 29.74 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 33.39 Mn |
| Jun 30, 2022 | 32.07 Mn |
| Mar 31, 2022 | 29.37 Mn |
| Dec 31, 2021 | 29.05 Mn |
| Sep 30, 2021 | 31.27 Mn |
| Jun 30, 2021 | 25.60 Mn |